Chemoradiation and Panitumumab for Esophageal Cancer

Inclusion Criteria: * Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastro esophageal junction * Surgical resectable (T2-3, N0-1, M0), as determined by Endoscopic Ultra Sound (EUS) and CT scan of neck, thorax and abdomen. * T1N1 tumors are eligible, T1N0 tumors and in situ carcinoma are not eligible * Tumor length longitudinal ≤ 10 cm and radial ≤ 5 cm * If tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction. The tumor must not extend more than 2 cm into the stomach. Gastric cancers with minor involvement of the GE junction or distal esophagus are not eligible * No invasion of the tracheobronchial tree or presence of tracheoesophageal fistula * Non pregnant, non-lactating female patients, not planning to become pregnant within 6 months after the end of treatment. * Age ≥ 18 and ≤ 75 * ECOG performance status 0 or 1 * Adequate hematological, renal, hepatic and pulmonary functions * Written, voluntary informed consent * Patients must be accessible to follow up and management in the treatment center Exclusion Criteria: * Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, or curatively treated in situ carcinoma of the cervix, or malignancy more than 5 years prior to enrollment * Pregnancy (positive serum pregnancy test) and lactation * Patient (male or…